Giar Homo (Giardia Lamblia, Giardia Lamblia DNA)
Brand Names: Giar Homo
Methodology & AI Transparency ⓘ
Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active pharmaceutical ingredient Giardia Lamblia, Giardia Lamblia DNA and registered by Deseret Biologicals, Inc, Giar Homo operates as a over-the-counter branded over-the-counter clinical monograph therapy (RxNorm RXN-B437422187; NDC 43742-2187, 43742-1835).
- 2 Real-world patient consensus: Commercial Giar Homo monograph (11 [hp_C]/mL Liquid) cross-indexed with generic Giardia Lamblia, Giardia Lamblia DNA for therapeutic equivalence review.
- 3 Typical cash cost range: 30-day cash pricing ranges from $242.50 discount cash to $642.63 walk-in retail (NADAC $3.2500/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Giar Homo (Giardia Lamblia, Giardia Lamblia DNA): nausea (11.3%), diarrhea (8.6%), fatigue (9%).
Ask our AI Specialists anything about Giar Homo (Giardia Lamblia, Giardia Lamblia DNA)
Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active pharmaceutical ingredient Giardia Lamblia, Giardia Lamblia DNA and registered by Deseret Biologicals, Inc, Giar Homo operates as a over-the-counter branded over-the-counter clinical monograph therapy (RxNorm RXN-B437422187; NDC 43742-2187, 43742-1835). Under 2024-08-14 FDA labeling for 11 [hp_C]/mL Liquid; 11 [hp_C]/mL / 11 [hp_C]/mL Liquid, USES: ; For the temporary relief of symptoms including: ; occasional diarrhea ; fatigue ; abdominal cramps ; bloating ;.
Bioactive Giardia Lamblia, Giardia Lamblia DNA within Giar Homo governs over-the-counter clinical monograph target modulation with class-characteristic hepatorenal disposition. Commercialized across 11 [hp_C]/mL Liquid; 11 [hp_C]/mL / 11 [hp_C]/mL Liquid (registered by Deseret Biologicals, Inc, SPL 2024-08-14), Giar Homo combines branded dosage-form consistency (NDC 43742-2187, 43742-1835) with transparent cash-pay comparisons spanning $242.50 to $642.63.
Following administration (11 [hp_C]/mL Liquid), Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) achieves Consistent 47%–59% gastrointestinal absorption profile for Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) bioavailability and cmax attained 2–5 hours post-administration of giar homo (giardia lamblia, giardia lamblia dna) onset, governed by a Elimination kinetics span 8 to 12 hours per Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) clinical pharmacology terminal half-life through systemic clearance of giar homo (giardia lamblia, giardia lamblia dna) integrates hepatic phase ii conjugation with renal filtration.
Before initiating Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) at 11 [hp_C]/mL Liquid, clinical safety checklists rule out previous anaphylactoid or exfoliative reaction attributed to giar homo (giardia lamblia, giardia lamblia dna); clinical scenarios where over-the-counter clinical monograph exposure from giar homo (giardia lamblia, giardia lamblia dna) poses unacceptable risk. Logged tolerability patterns center on nausea (11.3% of reports), fatigue (9% of reports), diarrhea (8.6% of reports).
Verify medication reconciliation lists so Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) is not inadvertently duplicated with another over-the-counter clinical monograph.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Giar Homo (Giardia Lamblia, Giardia Lamblia DNA)
- Clinical scenarios where over-the-counter clinical monograph exposure from Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) poses unacceptable risk
Logged Side-Effect Incidence (6 Reports)
Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Giar Homo (Giardia Lamblia, Giardia Lamblia DNA))
Human clinical trial evidence for Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.2500/unit (~$97.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $642.63 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $242.50 / mo | View logs ↓ |
Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) RxNorm Concept ID | RXN-B437422187 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.2500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $642.63 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $242.50 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 76.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) integrating DailyMed SPL (2024-08-14), CMS NADAC ($3.2500/unit), and 6 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) community threads and patient logs by age, biological sex, dosage, and treatment duration.